Lupin gets USFDA nod for generic version of Clobex lotion

Published On 2017-09-27 07:13 GMT   |   Update On 2021-08-18 09:06 GMT

New Delhi: Drug maker Lupin said it has received approval from the US health regulator to market anti-inflammatory Clobetasol Propionate lotion in the American market.


The Mumbai-based firm said in a statement that it has received final approval for its product from the US Food and Drug Administration (USFDA).
The company's product is a generic version of Galderma Laboratories' Clobex Lotion, which is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.


As per IMS MAT June data, Clobex had sales of USD 14.3 million in the US market.
Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News